Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVATACE-1: Bevacizumab (Avastin) as Inhibitor of Collateral Tumor Vessel Growth During Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC) a Pilot Trial.

Next Previous
X
Search
Trial Profile

AVATACE-1: Bevacizumab (Avastin) as Inhibitor of Collateral Tumor Vessel Growth During Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC) a Pilot Trial.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Doxorubicin; Ethiodized oil
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms AVATACE; AVATACE-1

    • Most Recent Events

    • 01 Nov 2010 Primary endpoint 'Progression-free-survival-rate' has not been met, accoridng to data presented at AASLD.
    • 01 Nov 2010 Results were presented at the 61st Annual Meeting of the Association for the Study of Liver Diseases.
    • 27 Apr 2010 Actual patient number (32) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top